Simple HPV swab or blood test may spot returning cervical cancer earlier
NCT ID NCT07493928
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study looks at whether testing for HPV DNA from a cervical swab or a blood sample can help find cervical cancer that has come back after radiotherapy. Researchers will follow 120 patients for two years after treatment, collecting samples at regular visits. The goal is to see how well these tests detect recurrence compared to standard exams and scans.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a simple, routine test to catch cervical cancer recurrence earlier after radiotherapy, potentially improving outcomes.
- What could go wrong
- This is an observational study, not a treatment trial. It is small (120 patients) and early, so results may not change practice immediately or apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 120 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2026
- Expected to finish
-
Feb 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients undergoing primary (chemo)radiation for cervical cancer
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient indicated for primary RT for cervical cancer * FIGO stage IB - IVA * Signed informed consent * Age ≥ 18 years * Administration of RT with curative intent Exclusion Criteria: * Clinical stage FIGO IA * Clinical stage FIGO IVB * History of radiotherapy in the pelvis * Hysterectomy performed before the start of radiotherapy (adjuvant RT) * History of HPV-associated malignancy in personal history * HIV or other significant immunodeficiency
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cell free DNA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
General Faculty Hospital in Prague
RECRUITINGPrague, 12800, Czechia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Radiation plus targeted antibody tested in older head and neck cancer patients
- Can software and expert review unlock curative radiation for Hard-to-Treat cancers?
- Can an HPV shot stop vulvar lesions from coming back?
- Tiny gadolinium particles aim to make brain radiation hit harder
- Can a Butter-Derived supplement protect the gut during cancer radiation?
- Can repeated MRI scans reveal how tumors respond to radiation?